REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

20/02/2020 15:30

RNS Number : 6576D
GlaxoSmithKline PLC
20 February 2020
 


GlaxoSmithKline plc (the 'Company')
Transaction notification




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


43,760


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP, Human Resources




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Following the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan, Ms Conrad received a cash amount of approximately £152,000 (less applicable tax withholding) which is equal to the market value of the number of Ordinary Shares which would otherwise have been transferred to her.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


9,168


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-19




f)


Place of the transaction
 


N/A




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


SVP & General Counsel




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053
 




b)


Nature of the transaction


The sale of ADSs to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$43.544


2,454


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


New York Stock Exchange (XNYS)
 




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


16,122


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications & CEO Office




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


4,309


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Jackson




b)


Position/status


PCA of Ms S Jackson (SVP, Global Communications & CEO Office)




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


1,111


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053
 




b)


Nature of the transaction


The sale of ADSs to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$43.544


33,055


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


New York Stock Exchange (XNYS)
 




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


65,213


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


31,324


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


4,309


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


21,650


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Waterhouse




b)


Position/status


CEO of ViiV Healthcare




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


5,909


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms V Whyte




b)


Position/status


Company Secretary




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's 2017 Performance Share Plan.
 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£16.597


4,309


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-02-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEBLFLBLLLBBK